Menu Search
Equities

Electromed Inc

ELMD:ASQ

Electromed Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)26.44
  • Today's Change-0.40 / -1.49%
  • Shares traded144.49k
  • 1 Year change+157.95%
  • Beta0.2343
Data delayed at least 15 minutes, as of Nov 12 2024 23:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Electromed Inc grew revenues 13.83% from 48.07m to 54.72m while net income improved 62.67% from 3.17m to 5.15m.
Gross margin76.26%
Net profit margin9.41%
Operating margin12.03%
Return on assets10.51%
Return on equity12.53%
Return on investment12.51%
More ▼

Cash flow in USDView more

In 2024, Electromed Inc increased its cash reserves by 118.12%, or 8.71m. The company earned 9.07m from its operations for a Cash Flow Margin of 16.57%. In addition the company generated 36.00k cash from financing while 395.00k was spent on investing.
Cash flow per share0.6757
Price/Cash flow per share37.65
Book value per share5.16
Tangible book value per share5.08
More ▼

Balance sheet in USDView more

Electromed Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio5.75
Quick ratio5.27
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 59.66%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)20.42
EPS (TTM) vs
TTM 1 year ago		59.23
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.